The Things Industries Celebrates 1.5 Million Connected Devices and Other Milestones During The Things Conference 2023
19.9.2023 17:00:00 EEST | Business Wire | Press release
The Things Industries, a global leader in LoRaWAN® Internet of Things (IoT) solutions, has announced 1.5 million devices connected to its robust network server infrastructure, The Things Stack, marking a new milestone in its journey towards operational excellence and product leadership in the LoRaWAN ecosystem. This and more announcements are being celebrated during the flagship event - The Things Conference, organized by The Things Industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230919065625/en/
The Things Industries has reached 1.5 million connected devices to its LoRaWAN Network Server (Graphic: Business Wire)
The company has emerged as a product leader and is widely respected for its operational excellence, uptime, and product completeness. Among its clients and partners are numerous Fortune 500 companies, utility companies, IoT product scale-ups, and a diverse range of system integrators.
This achievement underscores the company's commitment to product leadership and operational excellence in the market of LoRaWAN solution management software, and the ability to scale IoT projects for The Things Industries’ customers and partners. The Things Industries’ LoRaWAN platform is a global product that can be used in every industry vertical.
The recent report by Beecham Research validates the continued growth of LoRaWAN and the adoption across the world. As a global leader in the market of LoRaWAN network management software providers, The Things Industries validates these findings by seeing wide range adoption of the standard on its platform.
The Things Industries serve the market with its leading platform, The Things Stack Cloud, a managed LoRaWAN network server with advanced features and cloud capability that provides industry-leading uptimes with unlimited scalability. With the cloud capability, free and seamless upgrades come included.
The Things Conference, the company's flagship user event, will showcase the broad adoption and usage of the LoRaWAN standard and The Things Stack Cloud platform. The conference will feature over 100 device manufacturers, 110 speakers sharing their IoT experiences, and more than 60 concrete solutions with detailed business cases will be showcased. The Things Conference takes place on 21 and 22 September 2023 from 9 AM to 5 PM Central European Summer Time. The event will be streamed live worldwide.
Wienke Giezeman, CEO of The Things Industries, commented, "The Things Conference is a gathering where we celebrate hard-won successes in the LoRaWAN user space. IoT is a challenging field, and the level of innovation on display is growing every year. I anticipate engaging with the 1,000+ IoT innovators at our event."
About The Things Industries
Founded in 2015, The Things Industries is a leading provider of LoRaWAN IoT solutions, designed to offer secure and efficient connectivity. With a focus on driving efficiency and sustainability, the company estimates that its platform contributes to over $1 billion in efficiency gains for its customers.
For those interested in building IoT solutions based on LoRaWAN, The Things Industries offers a use case selector for product and service recommendations. To get started with the secure LoRaWAN Network Server, visit https://www.thethingsindustries.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919065625/en/
Contact information
Anastasia Grammatikopoulou, Marketing Manager, anastasia@thethingsindustries.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom